Financial Architects (New Jersey)’s Juno Therapeutics, Inc. JUNO Stock Holding History

Financial Architects (New Jersey)’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-500	Closed	-$23K	–	1671
2017 Q4	$23K	Buy	+500	New	+$24.9K	﹤0.01%	941
2017 Q3	–	Sell	-300	Closed	-$9K	–	1670
2017 Q2	$9K	Hold	300	–	–	﹤0.01%	1179
2017 Q1	$7K	Sell	300 -135	-31%	-$2.9K	﹤0.01%	1237
2016 Q4	$8K	Sell	435 -123	-22%	-$3.01K	﹤0.01%	1069
2016 Q3	$17K	Buy	558 +258	+86%	+$8.03K	﹤0.01%	886
2016 Q2	$12K	Hold	300	–	–	﹤0.01%	936
2016 Q1	$11K	Buy	+300	New	+$10.5K	﹤0.01%	740
2015 Q2	–	Sell	-200	Closed	-$12K	–	1276
2015 Q1	$12K	Buy	+200	New	+$9.71K	﹤0.01%	685

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Financial Architects (New Jersey)'s JUNO Position: Q1 2018 in Review

Financial Architects (New Jersey) sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 500 shares — an estimated $23K sold.

Financial Architects (New Jersey) first reported a position in JUNO in Q1 2015 and held it in 8 quarters. The position peaked at $23K in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Financial Architects (New Jersey) reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Financial Architects (New Jersey) sold 500 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $23K.
Financial Architects (New Jersey) first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 8 quarters.
Financial Architects (New Jersey)'s Juno Therapeutics, Inc. position peaked at $23K in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Financial Architects (New Jersey)'s 13F filing for Q1 2018, filed 23 Apr 2018.